In early December 2019, an outbreak of coronavirus disease 2019 (COVID-19) was recorded in Wuhan City, Hubei Province, China, caused by a novel severe acute respiratory coronavirus 2 syndrome (SARS-CoV-2). On January 30, 2020, the World Health Organization declared the outbreak a Public Health Emergency of International Concern. On February 14, 2020, 495 laboratories reported COVID-19 outbreaks, with 1,381 deaths. The cases began to be identified on December 8, 2019, and included some patients who worked or lived in the Huanan Seafood Wholesale Market. This virus is a member of the -coronavirus family, which is a large group of viruses found in nature. SARS-CoV-2, like other viruses, has many natural hosts, intermediate hosts, and end hosts. The management of viral infections would be significantly hindered as a result of this. SARS-CoV-2 has a high transmissibility and infectivity, as well as a low mortality rate, when compared to severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV). Prior skin conditions such as rosacea, eczema, atopic dermatitis, and neurodermatitis have worsened in some COVID-19 patients. Facial acne and rosacea developed or worsened as a result of the prolonged use of masks during the outbreak. The use of skin disinfectants on a regular basis has increased the incidence of contact dermatitis not only in COVID-19 patients, but also in healthy people and medical staff. To help people, several dermatologists in China are offering free online consultations. Specific treatment approaches for certain skin diseases should be considered during the epidemic. People with multiple skin conditions, such as psoriasis, are more likely to develop cardiovascular disease, depression, and other health issues, which may raise the risk of severe cases and death after COVID-19. In the current scenario, therapeutic drugs such as IL-17 inhibitors, which rapidly control skin lesions and have less side effects on immune functions than traditional immunosuppressants, can be considered first-line therapy. It is also based on some arguments that some biological agents could be useful in the treatment of novel coronavirus pneumonia, despite the fact that the therapeutic effectiveness of biological agents in both skin diseases and novel coronavirus pneumonia is still being studied in clinical trials. Skin rashes in COVID-19 patients have been documented all over the world. The rashes may occur in a variety of shapes and sizes, with some appearing as small red spots and others as larger flat or raised lesions. Some resemble beehives, while others resemble frostbitten feet. A ‘maculpapuar' rash, or one that is characteristic of viral infections such as measles, with red bumps on reddish skin, a hives-related ‘urticaria' rash, a lace-like or fishnet pattern ‘livedo' rash, a ‘vesicular eruption' or blistering rash, and a frostbite-like rash on toes, unofficially called ‘covid toes'.